The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | How risk assessment in myeloma is changing with the emergence of MRD
Mattia D’Agostino, MD, University of Turin, Turin, Italy, briefly discusses advances that have been made in the tools used to define risk in multiple myeloma, drawing focus on measurable residual disease (MRD), and how these novel prognostic tools may benefit patients in the future. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
